Research Progress on Epigenetics of Diabetic Cardiomyopathy in Type 2 Diabetes

Deng, Jianxin; Liao, Yunxiu; Jian-pin, Liu; Liu, Wenjuan; Yan, Dewen

doi:10.3389/fcell.2021.777258

Cited by 17 publications

(8 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several cases of hypermethylation or demethylation, histone modifications, and altered expression of noncoding RNA associated with diabetic cardiomyopathy in diabetic patients or rodents have been reported and reviewed elsewhere [ 169 , 170 , 171 ]. Here, we summarize the recent progress with therapeutic potential.…”

Section: Molecular Mechanism Of Diabetic Cardiomyopathymentioning

confidence: 99%

Emerging Therapy for Diabetic Cardiomyopathy: From Molecular Mechanism to Clinical Practice

et al. 2023

View full text Add to dashboard Cite

Diabetic cardiomyopathy is characterized by abnormal myocardial structure or performance in the absence of coronary artery disease or significant valvular heart disease in patients with diabetes mellitus. The spectrum of diabetic cardiomyopathy ranges from subtle myocardial changes to myocardial fibrosis and diastolic function and finally to symptomatic heart failure. Except for sodium–glucose transport protein 2 inhibitors and possibly bariatric and metabolic surgery, there is currently no specific treatment for this distinct disease entity in patients with diabetes. The molecular mechanism of diabetic cardiomyopathy includes impaired nutrient-sensing signaling, dysregulated autophagy, impaired mitochondrial energetics, altered fuel utilization, oxidative stress and lipid peroxidation, advanced glycation end-products, inflammation, impaired calcium homeostasis, abnormal endothelial function and nitric oxide production, aberrant epidermal growth factor receptor signaling, the activation of the renin–angiotensin–aldosterone system and sympathetic hyperactivity, and extracellular matrix accumulation and fibrosis. Here, we summarize several important emerging treatments for diabetic cardiomyopathy targeting specific molecular mechanisms, with evidence from preclinical studies and clinical trials.

show abstract

Section: Molecular Mechanism Of Diabetic Cardiomyopathymentioning

confidence: 99%

Emerging Therapy for Diabetic Cardiomyopathy: From Molecular Mechanism to Clinical Practice

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Over 70% of individuals with diabetes will develop some form of heart disease, such as acute coronary syndrome, during their lifespan (161). It is estimated that 12% of patients with diabetes eventually develop severe heart failure (HF) and often die due to DCM (162,163). Recent studies demonstrated that diabetes could increase the risk of HF 2-3 times and increase the death rate of HF by 2.5 times in individuals with diabetes compared with control individuals (164).…”

Section: The Role Of Epitranscriptomics In Diabetic Cardiomyopathymentioning

confidence: 99%

Emerging Role of Epitranscriptomics in Diabetes Mellitus and Its Complications

Geng

Yang

2022

Front. Endocrinol.

View full text Add to dashboard Cite

Diabetes mellitus (DM) and its related complications are among the leading causes of disability and mortality worldwide. Substantial studies have explored epigenetic regulation that is involved in the modifications of DNA and proteins, but RNA modifications in diabetes are still poorly investigated. In recent years, posttranscriptional epigenetic modification of RNA (the so-called ‘epitranscriptome’) has emerged as an interesting field of research. Numerous modifications, mainly N6-methyladenosine (m6A), have been identified in nearly all types of RNAs and have been demonstrated to have an indispensable effect in a variety of human diseases, such as cancer, obesity, and diabetes. Therefore, it is particularly important to understand the molecular basis of RNA modifications, which might provide a new perspective for the pathogenesis of diabetes mellitus and the discovery of new therapeutic targets. In this review, we aim to summarize the recent progress in the epitranscriptomics involved in diabetes and diabetes-related complications. We hope to provide some insights for enriching the understanding of the epitranscriptomic regulatory mechanisms of this disease as well as the development of novel therapeutic targets for future clinical benefit.

show abstract

“…So, it has been proposed that the balance between histone acetylation and deacetylation must be tightly regulated (114). Hence, epigenetics in cardiovascular research and therapy is an exciting and promising emerging research field (115).…”

Section: Role Of Epigenetics In Diabetic Hfmentioning

confidence: 99%

Molecular and cellular mechanisms in diabetic heart failure: Potential therapeutic targets

Mengstie

Abebe²,

Teklemariam³

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

Diabetes Mellitus (DM) is a worldwide health issue that can lead to a variety of complications. DM is a serious metabolic disorder that causes long-term microvascular and macro-vascular complications, as well as the failure of various organ systems. Diabetes-related cardiovascular diseases (CVD) including heart failure cause significant morbidity and mortality worldwide. Concurrent hypertensive heart disease and/or coronary artery disease have been thought to be the causes of diabetic heart failure in DM patients. However, heart failure is extremely common in DM patients even in the absence of other risk factors such as coronary artery disease and hypertension. The occurrence of diabetes-induced heart failure has recently received a lot of attention. Understanding how diabetes increases the risk of heart failure and how it mediates major cellular and molecular alteration will aid in the development of therapeutics to prevent these changes. Hence, this review aimed to summarize the current knowledge and most recent findings in cellular and molecular mechanisms of diabetes-induced heart failure.

show abstract

Research Progress on Epigenetics of Diabetic Cardiomyopathy in Type 2 Diabetes

Cited by 17 publications

References 106 publications

Emerging Therapy for Diabetic Cardiomyopathy: From Molecular Mechanism to Clinical Practice

Emerging Therapy for Diabetic Cardiomyopathy: From Molecular Mechanism to Clinical Practice

Emerging Role of Epitranscriptomics in Diabetes Mellitus and Its Complications

Molecular and cellular mechanisms in diabetic heart failure: Potential therapeutic targets

Contact Info

Product

Resources

About